Formulation and Systematic Optimisation of Polymeric Blend Nanoparticles via Box–Behnken Design
Pharmaceutics · 20.10.2025 · 17 (10) · 1351
DOI: 10.3390/pharmaceutics17101351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 20.10.2025. Verfasst von Basant Salah Mahmoud und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Egyptian government of a PhD scholarship.
Abstract (Originalsprache)
Background/Objectives: Despite the advantages of polycaprolactone (PCL) for drug delivery, it still lacks effective approaches to enhance its encapsulation of drugs. Blending PCL with less hydrophobic polymers can tailor physicochemical properties to overcome these limitations. This study, for the first time, integrates two beneficial approaches—polymer blending and Box–Behnken design (BBD) optimisation—to develop PCL-based blend nanoparticles (NPs) with enhanced encapsulation efficiency (EE), controlled particle size, and improved stability through surface charge modulation.
Methods
Drug-loaded blend NPs were developed using a double emulsion method, with different polymer ratios. A BBD model was employed to investigate the influential factors that control the size, charge, and EE.
Results
Blending PCL with a less hydrophobic polymer significantly improved EE, achieving 60.96% under optimal conditions. The BBD model successfully predicted conditions for obtaining NPs with optimum size, negative charge, and enhanced drug encapsulation. The drug amount was identified as the most influential factor for EE, while polymer amounts significantly impacted size and charge.
Conclusions
Careful control of polymer ratios, drug amount, and surfactant levels was shown to significantly influence particle size, surface charge, and EE, with the balanced 50:50 PCL:PLGA blend achieving optimal physicochemical performance. Using the BBD, the study identified the predicted optimal formulation consisting of 162 mg polymer blend, 8.37 mg drug, and 8% surfactant, which is expected to yield NPs with a size of 283.06 nm, zeta potential of −31.54 mV, and EE of 70%. The application of BBD allowed systematic evaluation of the factors and their interactions, providing robust predictive models.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
- Hormones Department, Institute of Medical Research and Clinical Studies, National Research Centre, El Buhouth St., Dokki, Cairo 12622, Egypt.
- Centre for Genomic Medicine, School of Biomedical Sciences, Ulster University, Coleraine BT52 1SA, UK.
ORCID-Profile: Basant Salah Mahmoud
Förderung
- Egyptian government of a PhD scholarship
Zitieren
APA
Mahmoud, B. S., & McConville, C. (2025). Formulation and Systematic Optimisation of Polymeric Blend Nanoparticles via Box–Behnken Design. Pharmaceutics, 17(10), 1351. https://doi.org/10.3390/pharmaceutics17101351
Vancouver
Mahmoud BS, McConville C. Formulation and Systematic Optimisation of Polymeric Blend Nanoparticles via Box–Behnken Design. Pharmaceutics. 2025;17(10):1351. doi:10.3390/pharmaceutics17101351
BibTeX
@article{Mahmoud2025,
author = {Mahmoud, Basant Salah and McConville, Christopher},
title = {Formulation and Systematic Optimisation of Polymeric Blend Nanoparticles via Box–Behnken Design},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {10},
pages = {1351},
doi = {10.3390/pharmaceutics17101351}
}
EUVIMED